Login

Register

  • Dates

  • Topics

  • Formats

  • Organiser

Organiser: EMJ GOLD
AI is becoming less of a buzzword and more of a key consideration for those in the pharmaceutical industry. For medical affairs professionals, the benefits of AI are growing – but how can they be harnessed? 
Interview by Jade Williams

In the dynamic realm of medical affairs, teams are tasked with a dual challenge: adapting to evolving industry needs while maintaining their core mission of educating and engaging healthcare professionals. At EMJ GOLD, we believe that medical affairs can be a transformative force, and EMJ offers innovative tools to help them succeed along the way, but AI is a road less travelled. To explore its potential, we asked three experts to share their insights on how AI will reshape medical affairs. Where will it have the greatest impact, and what are the potential challenges to watch out for?

Contributors:

  • Carlos Eid, Executive Director, International Medical Affairs, CV & ASCVD, Novartis 
  • Ankur Sharma, Vice President, Head of Medical Affairs, Medical Devices & Digital, Radiology, Bayer  
  • Ludmil Alexandrov, Chief Scientific Officer, io9 
Read Full Article

Reading this content is completely free

Enjoy Unlimited Access and Unlock
Additional Features with a Free Account

Join Now

You are attempting to log out of MyMA

Do you really want to log out?

Logout
Close